Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Jean-Jacques Kiladjian, MD PhD, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, MD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, Viktor Rossiev, MD, Petr Dulicek, MD, Árpád Illés, MD D.Sc, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiri Mayer, MD, Vera Yablokova, MD, Kurt Krejcy, MD, Hans Hasselbalch, MD, Robert Kralovics, PhD, Heinz Gisslinger, MD

Blood (2019) 134 (Supplement_1): 553.

https://doi.org/10.1182/blood-2019-122233

Published: 2019

Journal Articles

A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms

Robyn M. Scherber, MDMPH, Martin M. Goros, MS, Jonathan Gelfond, MD PhD, Amylou C. Dueck, PhD, Sarah F Christensen, MD, Hans Hasselbalch, MD, Holly L. Geyer, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2181.

https://doi.org/10.1182/blood-2019-126803

Published: 2019

Journal Articles

Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs

Vibe Skov, PhD, Marc JB Dam, Rasmus K Pedersen, Morten Andersen, PhD, Trine Alma Knudsen, MD, Zamra Sajid, Lasse Kjær, PhD, Christina Ellervik, MD PhD, Hans Hasselbalch, MD, Johnny T Ottesen, PhD

Blood (2019) 134 (Supplement_1): 2972.

https://doi.org/10.1182/blood-2019-126819

Published: 2019

Journal Articles

Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Torben A Kruse, Hans Hasselbalch, MD

Blood (2019) 134 (Supplement_1): 2978.

https://doi.org/10.1182/blood-2019-131698

Published: 2019

Journal Articles

Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Torben A Kruse, Hans Hasselbalch, MD

Blood (2019) 134 (Supplement_1): 5396.

https://doi.org/10.1182/blood-2019-130560

Published: 2019

Journal Articles

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Blood (2019) 134 (Supplement_1): 4202.

https://doi.org/10.1182/blood-2019-126164

Published: 2019

Journal Articles

Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients

Heinz Gisslinger, MD, Christoph Klade, Pencho Georgiev, Aleksander Skotnicki, MD PhD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, Viktor Rossiev, MD, Petr Dulicek, Arpad Illes, MD PhD, Halyna Pylypenko, MD, Liliya Sivcheva, Jiri Mayer, MD, Barbara Grohmann-Izay, MD, Hans Hasselbalch, MD, Robert Kralovics, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 475.

https://doi.org/10.1182/blood.V128.22.475.475

Published: 2016

Journal Articles

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Vikas Gupta, MD FRCP, FRCPath, Claire N. Harrison, Hans Hasselbalch, MD, Lisa Pieri, MD PhD, Steffen Koschmieder, MD, Francisco Cervantes, Weichao Bao, PhD, Stacey Kalambakas, MD, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Florian H. Heidel, MD

Blood (2015) 126 (23): 825.

https://doi.org/10.1182/blood.V126.23.825.825

Published: 2015

Journal Articles

A Heterogeneous Response Pattern to Interferon-alpha2 with Induction of a Significant Decrease in the Calreticulin Mutant Allele Burden in a Subset of Patients with Essential Thrombocythemia and Primary Myelofibrosis

Sabrina Cordua, MD, Lasse Kjaer, PhD, Morten Orebo Holmström, MD, Niels Pallisgaard, MSc, Vibe Skov, MSc, PhD, Hans Hasselbalch, MD

Blood (2015) 126 (23): 4057.

https://doi.org/10.1182/blood.V126.23.4057.4057

Published: 2015

Journal Articles

Are Chronic Myeloproliferative Neoplasms Associated with Age-Related Macular Degeneration?

Marie Bak, MD PhDstudent, Torben Lykke Sørensen, Esben Meulengracht Flachs, Ann-Dorthe Olsen Zwisler, Knud Juel, Henrik Frederiksen, Hans Hasselbalch, MD

Blood (2015) 126 (23): 4444.

https://doi.org/10.1182/blood.V126.23.4444.4444

Published: 2015

Journal Articles

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Giovanni Barosi, MD, Mohan Agarwal, MD, MNAMS, Sonja Zweegman, MD, PhD, Wolfgang Willenbacher, MD, Sima Pakstyte, MD, Reinier Raymakers, MD, PhD, Nathan Cantoni, MD, Ankur Modi, Mahmudul Khan, PhD, Jose Ricardo Perez, MD, Hans Hasselbalch, MD, Jose Pablo Vargas Viveros, MD, Camila C.G. Linardi, MD, PhD, Heinz Gisslinger, MD, Adelmo Henrique Daumas Gabriel, MD, Francesca Palandri, David Lavie, MD, Claire N Harrison, DM FRCP FRCPath

Blood (2012) 120 (21): 2844.

https://doi.org/10.1182/blood.V120.21.2844.2844

Published: 2012

Journal Articles

A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia

Blood (2012) 120 (21): 803.

https://doi.org/10.1182/blood.V120.21.803.803

Published: 2012

Journal Articles

The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,

Christophe Desterke, PhD, Costanza Bogani, PhD, Lisa Pieri, MD, Alessandro M. Vannucchi, MD, PhD, Bernadette Guerton, Christophe Martinaud, MD, Denis Clay, Jean-Jacques Lataillade, MD, PhD, Hans Hasselbalch, MD, PhD, Heinz Gisslinger, MD, PhD, Sophie Amsellem, PhD, Jean-Loup Demory, MD, Agnès Charpentier, MD, Brigitte Dupriez, Claude Boucheix, MD, PhD, Eric Rubinstein, PhD, Marie-Caroline Le Bousse-Kerdiles, PhD

Blood (2011) 118 (21): 3834.

https://doi.org/10.1182/blood.V118.21.3834.3834

Published: 2011

Journal Articles

FLT3 Mediated MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis

Christophe Desterke, Hans Hasselbalch, MD, PHD, Dominique Bordessoule, MD, PhD, Heinz Gisslinger, MD, PhD, Alessandro Vannucchi, MD, PhD, Olivier Pierre-Louis, Carole Tonetti, Philippe Dessen, PhD, Vladimir Lazar, MD, PhD, Bernadette Guerton, Denis Clay, William Vainchenker, MD, PhD, Stephane Giraudier, MD, PhD, Marie-Caroline Le Bousse-Kerdiles, PhD

Blood (2007) 110 (11): 1532.

https://doi.org/10.1182/blood.V110.11.1532.1532

Published: 2007

NARROW

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms

Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs

Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

A Heterogeneous Response Pattern to Interferon-alpha2 with Induction of a Significant Decrease in the Calreticulin Mutant Allele Burden in a Subset of Patients with Essential Thrombocythemia and Primary Myelofibrosis

Are Chronic Myeloproliferative Neoplasms Associated with Age-Related Macular Degeneration?

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia

The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,

FLT3 Mediated MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only